NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: GLAND · data 2026-10-30
Gland Pharma Ltd.
In plain words
Price: 2.4% below its 52-week high of ₹3,171.
Delivery: 57.3% of traded shares were kept for delivery over the last 10 sessions, against 53.7% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹6,725 cr |
| Net profit (last 12 months) | ₹1,129 cr |
| Sales growth, 3 years (yearly) | 21.1% |
| Profit growth, 3 years (yearly) | 9.6% |
Smart-money activity
45/100 · Building over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 55.2% over the last 20 sessions vs 41.0% in the 40 before (1.35x); shares delivered per day 0.72x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 34 schemes hold it, about ₹5,307 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 61/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend ● Results
- 17 Sept 26Deal Block deal: BOFA SECURITIES EUROPE SA bought ₹42.4 cr (net ₹0 cr) +4.8% next session
- 11 Aug 26Dividend Dividend ₹20 (ex-date) +8.4% next session
- 10 Aug 26Results Results board meeting +12.4% next session
- 15 May 26Results Results board meeting +13.6% next session
- 28 Jan 26Results Results board meeting +7.4% next session
- 3 Nov 25Results Results board meeting -0.9% next session
- 5 Aug 25Results Results board meeting -1.3% next session
- 20 May 25Results Results board meeting +5.9% next session
- 3 Feb 25Results Results board meeting -4.7% next session
- 4 Nov 24Results Results board meeting +11.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Gland Pharma Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.03, which is very low.
What is Gland Pharma Ltd.'s P/E ratio?
About 45.2, based on the last 12 months' earnings and a price of ₹3,095.9 (data 2026-10-30).
What is the 52-week high and low of Gland Pharma Ltd.?
The 52-week high is ₹3,171 and the 52-week low is ₹1,573.6.
Mutual funds holding Gland Pharma Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 34 schemes holding about ₹5,307 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large and Midcap Fund | SBI Mutual Fund | 2.28% | ₹923 cr |
| Nippon India Growth Mid Cap Fund | Nippon India Mutual Fund | 1.62% | ₹813 cr |
| NIPPON INDIA SMALL CAP FUND | Nippon India Mutual Fund | 0.66% | ₹534 cr |
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 1.15% | ₹493 cr |
| SBI Contra Fund | SBI Mutual Fund | 0.72% | ₹325 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 1.54% | ₹301 cr |
| Nippon India ELSS Tax Saver Fund | Nippon India Mutual Fund | 2.06% | ₹290 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.53% | ₹232 cr |
| Mirae Asset Large Cap Fund | Mirae Asset Mutual Fund | 0.52% | ₹185 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.96% | ₹174 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.85% | ₹108 cr |
| Mirae Asset Multicap Fund | Mirae Asset Mutual Fund | 1.99% | ₹107 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 3.40% | ₹103 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.69% | ₹94 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.47% | ₹90 cr |
Similar companies
Alkem Laboratories Ltd. (ALKEM) · Biocon Limited (BIOCON) · Abbott India Limited (ABBOTINDIA) · IPCA Laboratories Limited (IPCALAB) · Ajanta Pharma Limited (AJANTPHARM)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLAND in NSE Scanner →